🚀 VC round data is live in beta, check it out!
iZafe Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for iZafe Group and similar public comparables like Balsm Alofoq, Jin Medical International, Ortivus, Etropal and more.
iZafe Group Overview
About iZafe Group
iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.
Founded
2008
HQ
Employees
12
Website
Sectors
Financials (FY)
EV
$16M
iZafe Group Financials
iZafe Group reported last fiscal year revenue of $643K and negative EBITDA of ($1M).
In the same fiscal year, iZafe Group generated $258K in gross profit, ($1M) in EBITDA losses, and had net loss of ($2M).
iZafe Group P&L
In the most recent fiscal year, iZafe Group reported revenue of $643K and EBITDA of ($1M).
iZafe Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $643K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $258K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($1M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (201%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (280%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (278%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
iZafe Group Stock Performance
iZafe Group has current market cap of $16M, and enterprise value of $16M.
Market Cap Evolution
iZafe Group's stock price is $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16M | $16M | -8.3% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialiZafe Group Valuation Multiples
iZafe Group trades at 24.7x EV/Revenue multiple, and (12.3x) EV/EBITDA.
iZafe Group Financial Valuation Multiples
As of April 11, 2026, iZafe Group has market cap of $16M and EV of $16M.
Equity research analysts estimate iZafe Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
iZafe Group has a P/E ratio of (9.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 24.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (12.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (8.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 61.4x | XXX | XXX | XXX |
| P/E | — | XXX | (9.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (10.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified iZafe Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
iZafe Group Margins & Growth Rates
iZafe Group's revenue in the last fiscal year declined by (25%).
iZafe Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
iZafe Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (25%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (201%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (22%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 320% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
iZafe Group Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Balsm Alofoq | XXX | XXX | XXX | XXX | XXX | XXX |
| Jin Medical International | XXX | XXX | XXX | XXX | XXX | XXX |
| Ortivus | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
iZafe Group M&A Activity
iZafe Group acquired XXX companies to date.
Last acquisition by iZafe Group was on XXXXXXXX, XXXXX. iZafe Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by iZafe Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialiZafe Group Investment Activity
iZafe Group invested in XXX companies to date.
iZafe Group made its latest investment on XXXXXXXX, XXXXX. iZafe Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by iZafe Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout iZafe Group
| When was iZafe Group founded? | iZafe Group was founded in 2008. |
| Where is iZafe Group headquartered? | iZafe Group is headquartered in Sweden. |
| How many employees does iZafe Group have? | As of today, iZafe Group has over 12 employees. |
| Is iZafe Group publicly listed? | Yes, iZafe Group is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of iZafe Group? | iZafe Group trades under IZAFE B ticker. |
| When did iZafe Group go public? | iZafe Group went public in 2011. |
| Who are competitors of iZafe Group? | iZafe Group main competitors are Balsm Alofoq, Jin Medical International, Ortivus, Etropal. |
| What is the current market cap of iZafe Group? | iZafe Group's current market cap is $16M. |
| What is the current revenue of iZafe Group? | iZafe Group's last fiscal year revenue is $643K. |
| What is the current EV/Revenue multiple of iZafe Group? | Current revenue multiple of iZafe Group is 24.7x. |
| Is iZafe Group profitable? | No, iZafe Group is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.